Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Arellano
Jorge
J
Leteneux
Claudia
C
D000970:Antineoplastic Agents / Q000191:economics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003365:Costs and Cost Analysis; D000077143:Docetaxel; D016527:Drug Costs; D000069347:Erlotinib Hydrochloride; D005858:Germany; D005971:Glutamates / Q000191:economics*; D006147:Guanine / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D000068437:Pemetrexed; D047428:Protein Kinase Inhibitors / Q000191:economics*; D011799:Quinazolines / Q000191:economics*; D043823:Taxoids / Q000191:economics*
D000970:Antineoplastic Agents; D005971:Glutamates; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000068437:Pemetrexed; D000077143:Docetaxel; D006147:Guanine; D000069347:Erlotinib Hydrochloride